1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [fd20214c-4a76-4042-b312-8c89debcf5a1] => Array ( [runtime-id] => fd20214c-4a76-4042-b312-8c89debcf5a1 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [7f6b4922-0e3c-457f-8cd7-cc17f646009d] => Array ( [runtime-id] => 7f6b4922-0e3c-457f-8cd7-cc17f646009d [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;2a99ed02782a62da9029f1897f5d751b5d0f6fd5 ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [fd20214c-4a76-4042-b312-8c89debcf5a1] => Array ( [runtime-id] => fd20214c-4a76-4042-b312-8c89debcf5a1 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [7f6b4922-0e3c-457f-8cd7-cc17f646009d] => Array ( [runtime-id] => 7f6b4922-0e3c-457f-8cd7-cc17f646009d [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;2a99ed02782a62da9029f1897f5d751b5d0f6fd5 ) ) )Table 1:Demographic and clinical characteristics of the study population (N = 101 patients)
No.a No. (%) Median IQR Age (yr) 101 71 21.5 Sex 101 Men 38 (37.6%) Women 63 (62.4%) NIHSS score on admission 98 15 6 No. of CVRFs 81 1 1 Etiology of stroke 101 TOAST 1 17 (16.8%) TOAST 2 63 (62.4%) TOAST 3 5 (5%) TOAST 4 16 (15.8%) Clinical outcome 98 4 2 Good (mRS 0–3) 34 (33.7%) mRS 0 5 (5%) mRS 1 5 (5%) mRS 2 13 (12.9%) mRS 3 11 (10.9%) Poor (mRS 4–6) 64 (63.4%) mRS 4 39 (38.6%) mRS 5 14 (13.9%) mRS 6 11 (10.9%)
Note:—CVRF indicates cardiovascular risk factors; Trial of Org 10172 in Acute Stroke Treatment (TOAST) 1, large-artery atherosclerosis; 2, cardioemboly; 3, dissection; 4, unknown etiology.
↵a No. indicates number in which the parameter was available in this retrospective study.